Corcept Therapeutics IncorporatedCORTNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank44
3Y CAGR-37.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-37.2%/yr
Quarterly compound
Percentile
P44
Within normal range
vs 3Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 5.05% |
| Q3 2025 | 19.38% |
| Q2 2025 | 14.55% |
| Q1 2025 | 8.74% |
| Q4 2024 | 13.05% |
| Q3 2024 | 10.17% |
| Q2 2024 | 18.96% |
| Q1 2024 | 19.33% |
| Q4 2023 | 4.18% |
| Q3 2023 | 4.58% |
| Q2 2023 | -10.88% |
| Q1 2023 | 14.75% |
| Q4 2022 | 20.36% |
| Q3 2022 | -7.01% |
| Q2 2022 | 0.70% |
| Q1 2022 | 16.30% |
| Q4 2021 | 5.74% |
| Q3 2021 | 1.68% |
| Q2 2021 | 1.76% |
| Q1 2021 | 14.84% |
| Q4 2020 | -3.12% |
| Q3 2020 | 3.72% |
| Q2 2020 | -7.13% |
| Q1 2020 | 1.49% |
| Q4 2019 | 11.90% |
| Q3 2019 | -1.41% |
| Q2 2019 | 0.83% |
| Q1 2019 | 13.12% |
| Q4 2018 | 1.18% |
| Q3 2018 | 6.64% |
| Q2 2018 | 8.36% |
| Q1 2018 | 9.79% |
| Q4 2017 | 1.97% |
| Q3 2017 | 16.71% |
| Q2 2017 | -6.14% |
| Q1 2017 | 27.87% |
| Q4 2016 | 7.58% |
| Q3 2016 | -9.80% |
| Q2 2016 | 16.16% |
| Q1 2016 | 17.70% |